Australian cancer-focused epigenetics company EpiAxis Therapeutics has announced a collaboration with Canada’s largest and foremost research hospital, the University Health Network (UHN), to investigate a new approach to treating prostate cancer .
Under the agreement, EpiAxis Therapeutics will provide its lead peptide candidates for evaluation in UHN prostate cancer models, with the goal of significantly improving the ability to improve treatment and survival for men with prostate cancer. deadly prostate cancer (CaP).
EpiAxis Therapeutics CEO Dr. Jeremy Chrisp said that while next-generation genomic technologies have deepened understanding of the development and course of prostate cancer, they have arguably reached a therapeutic plateau.
“Most FDA-approved indications are for targets established in previous disease states, rather than new targets,” Dr. Chrisp said.
“Our first-class actives have a double action and target dormant cells resistant to chemotherapy while improving the immune response against persistent cells.
“EpiAxis is very pleased to provide our lead peptide candidates to UHN in hopes of accelerating innovation in the treatment of CaP.”
Dr. Hansen He, Principal Investigator at UHN’s Princess Margaret Cancer Center, will lead the project using EpiAxis’ lead peptide candidates.
Dr. He’s research program focuses on understanding the epigenetic mechanisms underlying cancer development, progression, and therapeutic response, with the goal of identifying epigenetic biomarkers and therapeutic targets to improve cancer outcomes. treatment of cancer patients.
“We are excited to collaborate with EpiAxis to target the epigenetic regulator LSD1 in advanced prostate cancer. This builds on our in-depth understanding of epigenetic mechanisms and the potent effect of LSD1 peptide inhibitors developed by EpiAxis,” said Dr. He.
“Travel aficionado. Twitter scholar. Writer. Extreme coffee guru. Evil pop culture fanatic.”